Scandinavian Biopharma announces successful results in placebo-controlled Phase I study of an oral, inactivated vaccine against diarrhea for travelers and children in developing countries

Travelers’ diarrhea is the leading cause of illness among international travelers to developing countries. Enterotoxigenic Escherichia coli (ETEC) bacteria are the primary cause of this disease. About 65 million people travel from industrialized countries to high-risk areas in the developing world. Of these, 30 to 50 percent, or approximately 27 million people, may experience at […]